Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Unresectable/Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 30
- Registration Number
- NCT06148402
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
Not yet recruiting
- Conditions
- Thyroid CarcinomaThyroid Nodule
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2023-11-30
- Target Recruit Count
- 800
- Registration Number
- NCT06146764
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
Completed
- Conditions
- Oral Cancer
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Target Recruit Count
- 206
- Registration Number
- NCT06143761
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Phase 3
Recruiting
- Conditions
- Early-stage Breast CancerBreast Cancer InvasiveHER2 Low Breast CarcinomaHormone-receptor-positive Breast Cancer
- Interventions
- Drug: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 160
- Registration Number
- NCT06144944
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Phase 2
Recruiting
- Conditions
- Oral CancerPD-1
- Interventions
- Drug: PD-1 with chemotherapyProcedure: upright surgery
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 40
- Registration Number
- NCT06130332
- Locations
- 🇨🇳
Sun yat-sen memorial hospital, Guangzhou, Guangdong, China
Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers
Recruiting
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 278
- Registration Number
- NCT06130319
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Procedure: Surgery for harvesting tumor-draining lymph nodesBiological: Tumor-draining lymph node-derived lymphocyte (LNL)Biological: Interleukin-2Biological: CamrelizumabDrug: Chemotherapeutic drug, ADC or PARP inhibitor
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Target Recruit Count
- 24
- Registration Number
- NCT06121557
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Procedure: Sentinel Lymph Node Biopsy (SLNB)Biological: Tumor-draining lymph node-derived lymphocyte (LNL)Biological: Interleukin-2
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Target Recruit Count
- 24
- Registration Number
- NCT06121570
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 20
- Registration Number
- NCT06120335
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
- Conditions
- Ovarian CancerNeoadjuvant ChemotherapyPrognostic Cancer Model
- Interventions
- Diagnostic Test: CRS scoringDiagnostic Test: Routine blood laboratory testing before treatment
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 465
- Registration Number
- NCT06120309
- Locations
- 🇨🇳
The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath